ARAF

Structure

A-Raf, a member of the Raf kinase family, shares a conserved domain architecture with B-Raf and C-Raf, comprising three conserved regions: CR1, CR2, and CR3.

• CR1 (Conserved Region 1): This N-terminal region contains the Ras-binding domain (RBD) and the cysteine-rich domain (CRD). The RBD facilitates interaction with activated Ras-GTP, anchoring A-Raf to the plasma membrane. The CRD, characterized by its zinc-binding motif, contributes to membrane association and protein-protein interactions Structural studies confirm the RBD and CRD function as a single entity during Ras binding.
• CR2 (Conserved Region 2): Positioned between CR1 and CR3, CR2 is a serine/threonine-rich regulatory segment containing phosphorylation sites (e.g., Ser259 in Raf-1) that modulate A-Raf's activity and interactions with 14-3-3 proteins. This region is critical for autoinhibition and activation dynamics.
• CR3 (Conserved Region 3): The C-terminal kinase domain exhibits the bilobal architecture characteristic of protein kinases, with an ATP-binding site between the N-terminal and C-terminal lobes. Structural analyses reveal similarities to tyrosine kinase-like (TKL) group members The RBD adopts a ubiquitin-like fold critical for Ras-GTP interaction., while the CRD's zinc-binding motif stabilizes membrane association. A-Raf's activity is regulated by phosphorylation-dependent 14-3-3 binding. and isoform dimerization, which is essential for MAPK pathway activation.

Function

A-Raf shares the canonical role of Raf kinases in the MAPK signaling cascade. Upon activation by Ras, A-Raf translocates from the cytosol to the plasma membrane, where it phosphorylates and activates MEK proteins. This activation leads to downstream ERK signaling and promotes cell cycle progression and proliferation.

Among the Raf isoforms, A-Raf exhibits the lowest kinase activity toward MEK proteins. This may be due to amino acid substitutions in a negatively charged region upstream of the kinase domain (the N-region), which result in low basal activity.

A-Raf is also the only Raf kinase known to be regulated by steroid hormones. In its inactive form, A-Raf is bound to 14-3-3 proteins in the cytosol; activation by Ras causes its translocation to the plasma membrane.

Beyond the MAPK pathway, A-Raf has additional functions. It inhibits MST2, a proapoptotic kinase, thereby suppressing apoptosis. This inhibitory activity is dependent on the expression of full-length A-Raf protein, which is maintained by the splicing factor hnRNP H.

A-Raf also regulates energy metabolism by interacting with pyruvate kinase M2 (PKM2), a key enzyme in cancer cell glycolysis. By promoting a conformational shift from the dimeric to the tetrameric form of PKM2, A-Raf enhances its enzymatic activity and shifts glucose utilization from biosynthesis toward energy production.

In addition, A-Raf has been implicated in endocytic membrane trafficking. Upon activation by receptor tyrosine kinases and Ras, A-Raf localizes to phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2)-rich membranes and signals to endosomes, leading to activation of ARF6, a key regulator of endocytosis.

Clinical significance

A-Raf may contribute to tumorigenesis through multiple mechanisms. In cancer cells, overexpression of hnRNP H enhances the production of full-length A-Raf, which inhibits MST2 and prevents apoptosis. The downregulation of hnRNP H, in contrast, leads to alternative splicing of the ARAF gene and loss of this anti-apoptotic activity.

A-Raf's regulation of PKM2 activity further links it to cancer metabolism. By promoting glycolytic flux toward pyruvate and lactate production, A-Raf may help sustain the high energy demands of rapidly proliferating tumor cells.

Because A-Raf modulates both apoptosis and metabolism—two critical hallmarks of cancer—it may represent a potential target for future cancer therapies.

Interactions

ARAF has been shown to interact with:

• EFEMP1,
• MAP2K2,
• PRPF6,
• RRAS,
• TIMM44, and
• TH1L.

References

References

1. (February 2021). "KRAS interaction with RAF1 RAS-binding domain and cysteine-rich domain provides insights into RAS-mediated RAF activation". Nature Communications.
2. (August 1996). "The solution structure of the Raf-1 cysteine-rich domain: a novel ras and phospholipid binding site". Proceedings of the National Academy of Sciences of the United States of America.
3. (February 2021). "KRAS interaction with RAF1 RAS-binding domain and cysteine-rich domain provides insights into RAS-mediated RAF activation". Nature Communications.
4. (July 2002). "14-3-3 antagonizes Ras-mediated Raf-1 recruitment to the plasma membrane to maintain signaling fidelity". Molecular and Cellular Biology.
5. (April 1997). "Exact and approximate rebinning algorithms for 3-D PET data". IEEE Transactions on Medical Imaging.
6. (April 1997). "Exact and approximate rebinning algorithms for 3-D PET data". IEEE Transactions on Medical Imaging.
7. (July 2004). "ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth". Journal of Cell Science.
8. (February 2021). "KRAS interaction with RAF1 RAS-binding domain and cysteine-rich domain provides insights into RAS-mediated RAF activation". Nature Communications.
9. (August 1996). "The solution structure of the Raf-1 cysteine-rich domain: a novel ras and phospholipid binding site". Proceedings of the National Academy of Sciences of the United States of America.
10. (July 2002). "14-3-3 antagonizes Ras-mediated Raf-1 recruitment to the plasma membrane to maintain signaling fidelity". Molecular and Cellular Biology.
11. (June 2018). "Overseas doctors must not be used just to fill rota gaps, says leading consultant". BMJ.
12. (March 2006). "Regulation and role of Raf-1/B-Raf heterodimerization". Molecular and Cellular Biology.
13. (2005-04-25). "A-Raf and Raf-1 work together to influence transient ERK phosphorylation and Gl/S cell cycle progression". Oncogene.
14. (2011-03-01). "Raf Family Kinases Old Dogs Have Learned New Tricks". Genes & Cancer.
15. (2007-09-07). "Unique N-region determines low basal activity and limited inducibility of A-RAF kinase: the role of N-region in the evolutionary divergence of RAF kinase function in vertebrates". The Journal of Biological Chemistry.
16. (1996-04-18). "Regulation of A-raf expression". Oncogene.
17. (2010-02-15). "Heterogeneous Nuclear Ribonucleoprotein H Blocks MST2-Mediated Apoptosis in Cancer Cells by Regulating a-raf Transcription". Cancer Research.
18. (2007-11-01). "Regulation of Pyruvate Kinase Type M2 by A-Raf: A Possible Glycolytic Stop or Go Mechanism". Anticancer Research.
19. (2009-02-27). "A-RAF Kinase Functions in ARF6 Regulated Endocytic Membrane Traffic". PLOS ONE.
20. (2010-02-15). "Heterogeneous Nuclear Ribonucleoprotein H Blocks MST2-Mediated Apoptosis in Cancer Cells by Regulating a-raf Transcription". Cancer Research.
21. (2008-03-13). "The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth". Nature.
22. (September 1986). "Pks, a raf-related sequence in humans". Proceedings of the National Academy of Sciences of the United States of America.
23. "Entrez Gene: ARAF V-raf murine sarcoma 3611 viral oncogene homolog".
24. (February 2003). "Novel raf kinase protein-protein interactions found by an exhaustive yeast two-hybrid analysis". Genomics.
25. (July 2000). "Isoform-Specific Localization of A-RAF in Mitochondria". Molecular and Cellular Biology.
26. (February 2002). "Identification of TH1 as an interaction partner of A-Raf kinase". Molecular and Cellular Biochemistry.
27. (February 2002). "Identification of interaction between MEK2 and A-Raf-1". Biochimica et Biophysica Acta (BBA) - Molecular Cell Research.